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ABSTRACT
Background
Some argue that by precluding individualized treatment, randomized clinical trials (RCTs)
provide substandard medical care, while others claim that participation in clinical research is
associated with improved patient outcomes. However, there are few data to assess the impact
of random treatment assignment on RCT participants. We therefore performed a systematic
review to quantify the differences in health outcomes between randomized trial participants
and eligible non-participants.
Methods and Findings
Studies were identified by searching Medline, the Web of Science citation database, and
manuscript references. Studies were eligible if they documented baseline characteristics and
clinical outcomes of RCT participants and eligible non-participants, and allowed non-
participants access to the same interventions available to trial participants. Primary study
outcomes according to patient group (randomized trial participants versus eligible non-
participants) were extracted from all eligible manuscripts. For 22 of the 25 studies (88%)
meeting eligibility criteria, there were no significant differences in clinical outcomes between
patients who received random assignment of treatment (RCT participants) and those who
received individualized treatment assignment (eligible non-participants). In addition, there was
no relation between random treatment assignment and clinical outcome in 15 of the 17 studies
(88%) in which randomized and nonrandomized patients had similar health status at baseline.
Conclusions
These findings suggest that randomized treatment assignment as part of a clinical trial does
not harm research participants.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Despite widespread reliance on randomized clinical trials
(RCTs), and claims that they represent the ‘‘gold standard’’
for assessing treatment efﬁcacy, ethical concern has been
raised about the impact of RCTs on participants [1–4].
Speciﬁcally, there is a perception that individual patients are
likely to have better outcomes when treatment decisions are
based on physicians’ clinical judgment, rather than random
assignment [1,2]. It has been claimed that by foregoing
individualized treatment assignment, the process of choosing
research participants’ treatments by random assignment
leads to an ‘‘inevitable compromise of personal care in the
service of obtaining valid research results’’ [1]. Further,
physician and patient concerns about random treatment
assignment are among the most frequently cited reasons for
refusal to enroll in RCTs [5–8].
While some commentators focus on the speciﬁc impact of
random treatment assignment, others have investigated the
broader topic of differences in clinical outcomes between
research participants and ‘‘real’’ patients in the community
setting. Some studies have suggested that research partic-
ipation may be associated with improved clinical outcomes
[9–14]. These data have led some to recommend trial
participation as a means to better treatment [15]. For
instance, the National Comprehensive Cancer Network’s
clinical practice guidelines in oncology state that ‘‘the best
management for any cancer patient is in a clinical trial’’ [15].
Yet these conclusions are not based on strong evidence [16].
In particular, comparisons of research participants versus
non-participants often include non-participants who do not
meet trial eligibility criteria [16]. Because of stringent
eligibility criteria, trial participants tend to be younger and
healthier than non-participants in the community [16–18].
Trial participation may also be the only means of access to
some therapies: if the investigational therapy is available only
in the research setting and turns out to be superior to
existing therapies, trial participants who were allocated to the
newer agent would be more likely to beneﬁt. Further, the
supportive clinical care that participants receive as part of
research in resource-rich settings associated with some
clinical trials may also be associated with superior outcomes.
Recognizing these ﬂaws in the existing data, a recent review
of the literature called for more studies that assess the impact
of participation in clinical research on patient outcomes in a
methodologically rigorous manner [16].
It is particularly timely to disentangle the issues surround-
ing the effect of research participation on patients. There has
recently been increased emphasis on designing trials that
compare commercially available, clinically relevant alterna-
tives [19–21]. Some authors have advocated substantial
increases in funding of ‘‘pragmatic’’ trials enrolling large
numbers of patients in community practice settings [19].
Additionally, Medicare’s policy has recently been modiﬁed so
as to provide reimbursement for some new therapies only if
patients receive them in the setting of a clinical trial [22].
Unlike in the previous paradigm, which viewed randomized
trials as a tool to evaluate the efﬁcacy of novel therapeutic
agents, these innovations will likely result in many more
patients encountering the decision of trial enrollment in the
setting of routine clinical care. Prospective participants who
are asked to participate in these pragmatic trials will have to
decide whether to receive therapy that was selected via
randomization or to select treatment with the input of their
clinician.
Given the increased emphasis on recruiting large numbers
of patients into trials, it is important to consider the question
of enrollment from the perspective of patients who meet all
eligibility criteria and are asked to enroll. If they agree to
have their treatment selected at random, rather than by their
clinicians or themselves, will they be more likely to
experience adverse outcomes? We sought to answer this
question by examining the potential risks associated with
random treatment allocation, rather than delineating differ-
ences between trial participants and non-participants [16,18].
While numerous studies have demonstrated the differences
between trial participants and their counterparts in the
community, few have focused speciﬁcally on the impact of
random treatment assignment. Speciﬁcally, we were inter-
ested in the group of patients who were eligible for
participation in an RCT but could also receive either of the
therapies offered in the RCT even if they refused to enroll.
We conducted a systematic review of published randomized
controlled trials to compare the clinical outcomes of
randomized patients and nonrandomized patients who were
eligible for the same trial, were cared for in the same clinical
setting, and received the same agents available to trial
participants.
Methods
Selection of Studies
We conducted a Medline search to identify studies that (1)
included only patients who were eligible for trial partic-
ipation, (2) included only patients who were cared for at the
same institutions and at the same time in which the
randomized trial was recruiting, (3) allowed non-partic-
ipants access to the agents used in the trial, (4) provided
outcome data for both trial participants and eligible non-
participants, and (5) recruited all participants in a similar
manner.
The Medline search employed 23 unique combinations of
terms and strings of terms (see Protocol S1). We focused a
signiﬁcant portion of our Medline search on identifying
studies that met our deﬁnition of comprehensive cohort
study design (see Protocol S1 for terms and phrases). The
comprehensive cohort study design, also called the partially
randomized patient preference trial design, offers eligible
research participants the chance to refuse randomization but
receive either the study intervention or the control inter-
vention per study protocol [23]. In addition, we used the
references of relevant manuscripts, authors’ own biblio-
graphic libraries, and Web of Science to identify frequently
cited researchers and papers.
The Medline search identiﬁed 1,505 studies; the Web of
Science search identiﬁed 371 studies. Of these 1,876 studies,
the titles of 1,555 were identiﬁed by the two reviewers as
potentially appropriate for inclusion in the current analysis.
The abstracts of these 1,555 studies were assessed by two
authors for appropriate content and relevant methodology.
The full texts of 48 potentially suitable manuscripts were
retrieved and assessed. Of these, 25 studies met the eligibility
criteria.
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Randomization and Patient OutcomeData Analysis
An explicit abstraction instrument was used to obtain
baseline characteristics of the RCT participants and eligible
non-participants and primary clinical outcomes. Outcomes
were restricted to the primary outcome listed in each
manuscript; if more than one primary outcome was speciﬁed,
the ﬁrst one listed was used. To compare outcomes across
studies, all study outcomes were standardized to ‘‘adverse’’
outcomes, e.g., for studies that reported survival, we converted
probability of survival to probability of death. Most of the
studies had dichotomous outcomes that enabled the calcu-
lation of odds ratios; those that did not were analyzed
separately. In the two studies in which outcomes were
expressed only as rates rather than as frequency counts, the
stated proportion of people in each group who experienced
the study outcome was multiplied by the number at baseline to
estimate the frequency [24,25]. In one study, non-participants
were able to select from three treatment options, only two of
which were part of the RCT. For this study, we included data
only from non-participants who received one of the two
treatments that were part of the RCT [25].
Because the relation between trial participation and
clinical outcomes might be confounded by differences in
baseline health status, we categorized the studies into three
mutually exclusive groups: those in which the RCT partic-
ipants were, overall, less healthy than eligible non-partic-
ipants at baseline, those in which there was no clear
difference in baseline health status, and those in which RCT
participants were, overall, healthier at baseline. Two clini-
cians, using an implicit schema involving examination of
baseline clinical and demographic characteristics of random-
ized and nonrandomized patients, independently categorized
each study according to whether there was a balance of
important prognostic factors between groups. Disagreements
were resolved by consensus.
The odds ratios of experiencing the primary clinical
outcome for RCT participants versus eligible non-partic-
ipants were calculated using SAS 8.1 [26]. A Breslow–Day chi-
square statistic indicated that it would be inappropriate to
aggregate the results of studies with dichotomous outcomes
because of heterogeneity. Thus, the outcomes are presented
simply by study, according to baseline differences.
Results
A total of 25 articles met the inclusion criteria and were
selected for data abstraction. The dates of publication ranged
from 1984 to 2002; the majority (80%) were published in 1990
or later. There was a broad range of conditions under
investigation, and types of studies, including surgical trials,
drug trials, and trials of counseling. The most common
specialties represented were oncology (six studies), cardio-
vascular disease (ﬁve studies), and obstetrics/gynecology (ﬁve
studies). The total number of eligible patients across all
studies was 17,934 (range: 79 to 3,610); the proportion of
eligible patients who agreed to be randomized ranged from
29% to 89% (average: 45 %; median: 47 %). The primary
outcomes of interest varied across studies; the most common
were mortality (9/25), acceptability of treatment (5/25), and
proportion of time or number of days with a given condition
(2/25).
Baseline Characteristics
Table 1 shows the study intervention and enrollment data
for all 25 studies, categorized according to baseline clinical
and sociodemographic characteristics. There were no clear
differences in baseline health status between RCT partic-
ipants and eligible non-participants in 17 studies. In one
study, RCT participants were healthier than eligible non-
participants at baseline, and in seven studies RCT partic-
ipants were less healthy at baseline than eligible non-
participants. There was no signiﬁcant relation between the
proportion of eligible patients who agreed to be randomized
and the occurrence of differences in baseline health status of
randomized versus nonrandomized patients. The mean
proportion of eligible patients who agreed to be randomized
in the seven studies categorized as ‘‘RCT patients less
healthy’’ was 48.9%, while the mean in the 17 studies with
no baseline differences was 43.5% (p ¼ 0.61).
Differences in clinical sociodemographic characteristics
between groups also varied in magnitude and signiﬁcance.
For instance, in the Bypass Angioplasty Revascularization
Investigation of angioplasty versus coronary artery bypass
graft, RCT participants were signiﬁcantly more likely than
non-participants to have a history of myocardial infarction
(55% versus 51%), heart failure (9% versus 5%), or diabetes
(19% versus 17%) [24]. Signiﬁcant differences in race were
found in two studies: the study by Marcus and colleagues
included more non-whites in the eligible, nonrandomized
group (10% versus 24%; p ¼ 0.008), and the Bypass
Angioplasty Revascularization Investigation included more
non-whites in the RCT group (10% versus 6%, p , 0.001)
[24,27,28].
Outcomes
In 22 of the 25 studies (88%), there were no signiﬁcant
differences in clinical outcomes between patients whose
treatment was selected by randomized allocation and those
whose treatment was selected on the basis of clinical
judgment and/or patient preferences (Table 2; Figure 1).
There were no signiﬁcant differences in clinical outcomes
between randomized and nonrandomized patients in 15 of
the 17 studies (88%) in which there were no clear baseline
differences in health or sociodemographic status. Similarly,
there were no signiﬁcant differences in clinical outcomes
between randomized and nonrandomized patients in six of
the seven studies in which RCT participants were sicker than
non-participants at baseline (86%; chi-square test, p . 0.05
for comparison with the ‘‘no clear baseline differences’’
group).
In Feit et al.’s analysis of the data from the Bypass
Angioplasty Revascularization Investigation [24], randomized
patients were more likely to have risk factors for adverse
outcomes at baseline: they were more likely to have
congestive heart failure, prior myocardial infarction, or
diabetes, and were more likely to be non-white and less
educated. The 7-y mortality in the randomized group was
17.3%, compared with 14.5% in the nonrandomized group
(relative risk: 1.19; 95% conﬁdence interval [CI]: 1.03, 1.39)
[24]. In Melchart et al.’s study of acupuncture versus
midazolam as pretreatment for gastroscopy [29], there were
no signiﬁcant differences in baseline health status between
randomized and nonrandomized groups. Randomized pa-
tients were more likely than nonrandomized patients to state
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Randomization and Patient Outcomethat they would not undergo the same treatment again
(34.6% versus 15.3%; relative risk: 2.27; 95% CI: 1.06, 4.84).
Similarly, in Blichert-Toft’s study of mastectomy versus
breast-conserving surgery for breast cancer [30], randomized
patients were more likely than nonrandomized patients to
experience the outcome of cancer recurrence (13.7% versus
6.6%), although the difference was of borderline signiﬁcance
(relative risk: 2.08; 95% CI: 1.07, 4.02).
In the single study in which randomized patients were
categorized as having a better baseline health status than
Table 1. Study Characteristics
Outcome Authors Intervention Total
Eligible
Patients
Patients Consenting to
Randomized Treatment
Allocation
N Percent
of Eligible
Randomized patients
less healthy at baseline
Hallstrom et al. [50] (AVID) Implantable cardioverter defibrillators
versus drug therapy for ventricular
fibrillation or ventricular tachycardia
2,168 1,190 54.9%
King et al. [51] (EAST) PTCA versus CABG for multivessel
coronary artery disease
842 392 46.6%
Cooper et al. [52] TCRE versus medical management
for heavy menstrual bleeding
227 187 82.4%
Marcus [27]/Paradise et al. [28] Adenoidectomy versus antimicrobial
drugs for otitis media
212 99 46.7%
Feit et al. [24] PTCA versus CABG for multivessel
coronary artery disease
3,610 1,796 49.8%
Chilvers et al. [53] Counseling versus medication for mild
to moderate major depression
323 103 31.9%
Bain et al. [54] Local anesthesia plus intravenous sedation
versus general anesthesia for microwave
endometrial ablation
123 36 29.3%
No clear difference
between randomized
and nonrandomized
patients at baseline
CASS [55] Prompt coronary artery bypass surgery
versus medical treatment with possible
surgery later for angina pectoris
2,099 780 37.2%
Paradise et al. [56] Surgery versus medication for recurrent throat infection 187 91 48.7%
Link et al. [57] Adjuvant chemotherapy versus observation
in children with osteosarcoma of the extremity
113 36 31.9%
Blichert-Toft et al. [30] Breast-preserving surgery versus mastectomy
for mammary carcinoma
847 662 78.2%
Henshaw et al. [58] Medical abortion versus vacuum aspiration
for pregnancy termination
363 195 53.7%
Nicolaides et al. [59] Chorionic villus sampling versus amniocentesis
for fetal karyotyping at 10–13 wk gestation
1,301 488 37.5%
McKay et al. [60] Outpatient versus inpatient rehabilitation
for male alcoholics
663 48 7.2%
Schmoor et al. [61] (GBSG-2) Three or six CMF plus tamoxifen versus
three or six CMF for breast cancer
720 473 65.7%
Schmoor et al. [61] (GBSG-3) Six CMF plus radiotherapy versus six
CMF for breast cancer
328 199 60.7%
de C Williams et al. [62] Inpatient versus outpatient chronic
pain management
412 121 29.4%
Urban et al. [63] (SMASH) Emergency revascularization versus initial
medical stabilization to treat shock
complicating acute myocardial infarction
79 55 69.6%
Mosekilde et al. [64] HRT versus no HRT to reduce fracture incidence
in postmenopausal women
2,016 1,006 49.9%
Rovers et al. [65] Ventilation tubes or watchful waiting for otitis media 386 187 48.4%
Wieringa–de Waard et al. [66] Expectant management versus surgical evacuation
for first trimester miscarriage
427 122 28.6%
Kerry et al. [67] Radiography referral versus no radiography
referral for low back pain
375 125 26.3%
Bijker et al. [25] Radiotherapy plus local excision versus local excision
(mastectomy also in control group) for breast cancer
390 122 31.3%
Melchart et al. [29] Acupuncture versus midazolam for gastroscopy 98 26 26.5%
Randomized patients
healthier than nonrandomized
patients at baseline
Antman et al. [31] Surgery/radiotherapy and Doxorubicin versus
observation for sarcoma
90 42 46.7%
CABG, coronary artery bypass graft; CMF, cyclophosphamide, methotrexate, and fluorouracil; HRT, hormonal replacement therapy; PTCA, percutaneous transluminal coronary angioplasty;
TCRE, transcervical resection of the endometrium.
DOI: 10.1371/journal.pmed.0030188.t001
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Randomization and Patient Outcomenonrandomized patients, there was a nonsigniﬁcant trend
towards the randomized patients being less likely to
experience disease recurrence or death (odds ratio for
randomized versus nonrandomized: 0.35; 95% CI: 0.12, 1.01)
[31].
Discussion
When there are several treatment options available, and
there is uncertainty about which one is superior, it is assumed
that individualized treatment assignment—in which clini-
cians consider the health status and preferences of each
patient and incorporate them into a recommendation—is
more likely to yield desirable outcomes. This is why doctors
don’t ﬂip coins, and this is also why some may assume that
randomization as part of a trial is harmful. In 23 of the 25
published clinical trials that met inclusion criteria, there were
no signiﬁcant differences in the likelihood of experiencing
the primary study outcomes between patients whose treat-
ment was determined by random allocation versus those
whose treatment was selected on the basis of clinical
judgment and/or patient preferences. More importantly, in
15 of the 17 studies in which randomized and nonrandomized
patients were classiﬁed as having similar health status at
baseline, there were no signiﬁcant differences between these
groups in clinical outcomes. These data contradict the
perception that random treatment assignment as part of a
clinical trial is harmful to research participants.
Table 2. Clinical Outcome in Randomized and Nonrandomized Patients
Outcome Authors Primary Outcome Percent of
Randomized
Patients with
Outcome
Percent of
Nonrandomized
Patients with
Outcome
Risk Ratio of
Bad Outcome
(Randomized
versus Registry)
Ratio 95% CI
Lower
Bound
95% CI
Upper
Bound
Randomized patients
less healthy at baseline
Hallstrom et al. [50]/
Kim et al. [68] (AVID)
Cumulative mortality 23.2% 23.4% 0.99 0.85 1.16
King et al. [51] (EAST) 3-y mortality 6.6% 6.0% 1.11 0.66 1.86
Cooper et al. [52] Treatment not acceptable at 4 mo 36.4% 27.5% 1.32 0.77 2.26
Feit et al. [24] 7-y mortality 17.3% 14.5% 1.19 1.03 1.39
Chilvers et al. [53] Lack of a rating of ‘‘good or moderate’’
global mental health outcome at 12 mo
39.8% 34.6% 1.15 0.85 1.55
Bain et al. [54] Percent not finding intervention
acceptable
8.3% 3.4% 2.42 0.51 11.41
Marcus [27]/
Paradise et al. [28]
Proportion of time with otitis media NSD
No clear difference
between randomized
and nonrandomized
patients at baseline
CASS [55] Percent dead at 5 y 7.9% 8.0% 0.99 0.73 1.34
Link et al. [56] Relapse or death 58.3% 40.3% 1.45 0.98 2.14
Blichert-Toft et al. [30] Recurrence of cancer 13.7% 6.6% 2.07 1.07 4.02
Henshaw et al. [58] Would not do same treatment again;
unacceptability
21.5% 14.3% 1.51 0.96 2.38
Nicolaides et al. [59] Spontaneous loss, gestation at
delivery, birthweight
3.5% 4.6% 0.77 0.44 1.34
Urban et al. [63] (SMASH) 30-d all-cause mortality 72.7% 50.0% 1.52 0.96 2.40
Mosekilde et al. [64] 5-y cumulative incidence of fractures 7.8% 7.7% 1.00 0.74 1.36
Wieringa–de Waard et al. [66] Complications of procedure 4.9% 6.2% 0.79 0.32 1.93
Kerry et al. [67] Patient dissatisfaction at 6 wk 26.4% 24.9% 1.06 0.75 1.50
Bijker et al. [25] Percent with local recurrence
within 4 y
11.5% 8.2% 0.59 0.30 1.14
Melchart et al. [29] Would not do same treatment
next time
34.6% 15.3% 2.27 1.06 4.84
Paradise et al. [56] Episodes of throat infection at 1 y NSD
de C Williams et al. [62] Physical functioning, drug use,
depression at 1 y
NSD
McKay et al. [60] Mean number of drinking days NSD
Rovers et al. [65] Decibels of improvement in
hearing level
NSD
Schmoor et al. [61] (GBSG-2) 5-y recurrence or death NSD
Schmoor et al. [61] (GBSG-3) 5-y recurrence or death NSD
Randomized patients healthier
than nonrandomized patients
at baseline
Antman et al. [31] 4-y disease or death 26.2% 50.0% 0.52 0.27 1.01
NSD, no statistically significant difference.
DOI: 10.1371/journal.pmed.0030188.t002
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Randomization and Patient OutcomeThe ﬁnding that randomized research participants and
non-participants tend to achieve similar clinical outcomes
also contradicts prior studies suggesting that trial participa-
tion may be associated with superior clinical outcomes [9–14].
Many of the previous studies that reported such a difference
failed to account for the numerous differences between
clinical care and clinical research that may inﬂuence patient
outcomes, including the fact that research participants are
often younger, healthier, and treated by clinicians with more
experience in treating patients with the condition of interest.
Speciﬁcally, we restricted the present analysis to studies that
included only patients who were eligible for RCT participa-
tion and had access to similar treatments whether or not they
chose to enroll in the RCT. Hence, while our study sample
was therefore restricted to a relatively small subset of RCTs,
our ﬁndings suggest that the purported beneﬁt of trial
participation is probably due to baseline differences between
participants and non-participants, or to differences in treat-
ments received.
All of the studies included in the present analysis allowed
access to the experimental therapies to patients who refused
trial enrollment. It is unclear whether our results can be
generalized to randomized trials that include newer, and
potentially more efﬁcacious, therapies that are not available
outside the research setting. However, a recent analysis found
that only 36% of trials presented at an annual meeting of the
American Society of Clinical Oncology yielded ‘‘positive’’
results [32]. These ﬁndings contradict the widespread
assumption that access to experimental therapies is beneﬁcial
[33–38]. Future work should explore whether participation in
randomized trials of otherwise unavailable agents is associ-
ated with superior clinical outcomes.
While our comprehensive and systematic search identiﬁed
far more manuscripts than prior reviews of this topic that we
are aware of, our ﬁnal sample size is small relative to the
number of RCTs conducted annually [39]. As a result,
although our ﬁndings were consistent across disease entities
and different types of intervention, they may not be
generalizable. As noted in prior reviews, many of the primary
studies did not control for differences in baseline health
characteristics [16,39]. We used an implicit, dual review
approach to account for this potential bias, stratifying
manuscripts according to baseline differences between trial
participants and non-participants. Ideally, future work
employing primary data would enable multivariate analysis
of patient-level information, to account for important
patient characteristics that may affect patient outcomes.
The increasing use of electronic medical records represents a
tremendous opportunity for establishing longitudinal regis-
try databases to facilitate follow-up of patients who are
offered trial enrollment, yet decline.
Our results should be interpreted with several consider-
ations in mind. We restricted our analysis to the primary
outcomes assessed in the included studies. In particular, many
studies assessed the outcome of mortality, and there may have
been differences in the probability of other adverse events,
satisfaction, or quality of life between RCT participants and
non-participants. Similarly, clinical trials may include addi-
tional research procedures, such as blood draws and lumbar
punctures that do not affect patient outcomes but that pose
burdens to participants. Additionally, random assignment
refers only to the investigational agent. Even among RCT
participants, clinician-investigators generally have some
latitude regarding other aspects of care that are administered
to their patients and can therefore provide individualized
care that consists of interventions that are distinct from the
investigational agent. Similarly, clinicians may halt existing
treatment for patients who are offered a choice of enrolling
Figure 1. Relative Risk of Experiencing Primary Outcome According to RCT Participation
Asterisks indicate statistical significance. The relevant references for the studies listed along the x-axis are as follows: AVID [50,68], EAST [51], Cooper
[52], BARI [24], Chilvers [53], Bain [54], CASS [55], Link [57], Blichert-Toft [30], Henshaw [58], Nicolaides [59], SMASH [63], Mosekilde [64], Kerry [67], Bijker
[25], Melchart [29], and Antman [31].
DOI: 10.1371/journal.pmed.0030188.g001
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Randomization and Patient Outcomein a study. In these instances, if a patient is provided one of
the treatment interventions offered in the study—whether
selected with randomization or by patient choice—it is
possible that the initial treatment may have been superior
to either of the treatments under investigation. Further,
publication bias might have yielded underestimates of
differences between RCT participants and eligible non-
participants, as investigators may have been reluctant to
report data from the non-participants in their registries if
they did not support the generalizability of their RCTs.
Finally, there may have been important differences in health
status between randomized and nonrandomized patients that
were not reported by the investigators. However, given that
the vast majority of the study samples in our sample found no
difference in health outcome between groups, one would
have to invoke a systematic over- or underestimation of
health status in the randomized groups across multiple
studies in order to instill bias in this synthesis.
Numerous studies indicate that RCT participants often fail
to understand that their treatments will be determined by
random assignment [18,40–42]. For example, a recent analysis
found that half of parents who decided whether to enroll
their children in a leukemia trial did not understand that
treatment allocation would be determined by chance [18].
The failure to understand randomization is often regarded as
part of a broader phenomenon, termed the ‘‘therapeutic
misconception,’’ according to which individuals assume that
research treatments are based on physicians’ decisions
regarding what is best for them [1,43]. In this context, our
ﬁndings have important implications for the informed
consent process. In addition to explaining randomization,
investigators should also explain that, in general, there is little
evidence to support that participating in randomized trials is
either helpful or harmful.
What do our ﬁndings say about the impact of clinical
judgment and patient preferences on clinical outcomes?
Although clinicians and patients may be reluctant to forego
clinical decision-making, our data suggest that undergoing
randomization, rather than individualized treatment recom-
mendations by clinicians, is not harmful. This conclusion calls
into question clinicians’ ability to determine which therapy is
superior for their patients in the setting of clinical equipoise,
i.e., when there is uncertainty in the expert community about
which treatment is superior for patients in general [44]. It has
also been suggested that some patients who are not randomly
assigned to a treatment may achieve a better outcome not
because of an objective therapeutic effect, but because they
were assigned to the treatment arm they preferred—a logical
extension of the placebo effect [45]. To account for this
possible ‘‘preference effect,’’ some have called for incorpo-
rating patient treatment preferences into the analysis phase
of RCTs [45]. Our data provide preliminary evidence that this
preference effect does not bias the outcomes of RCTs:
patients who received a treatment preferred by themselves
or their clinicians did not experience superior outcomes.
These ﬁndings are consistent with the result of a recent
review in which the authors stratiﬁed patients according to
treatment received and then compared the outcome of
patients who were randomized versus those who selected
each therapy [46].
A critical barrier to enrolling patients in research studies is
the fact that many patients are not even asked to participate
[47]. One reason why physicians are reluctant to recruit their
own patients is their reluctance to forego individualized
treatment decisions for their patients [7,48]. This reluctance
is especially important because physician recommendations
are among the strongest predictors of trial enrollment [49].
The current ﬁndings suggest that in the setting of clinical
equipoise, randomized treatment allocation as part of an
RCT is unlikely to be harmful This does not imply that all
research is not risky, as the risks and beneﬁts of experimental
treatment may vary substantially between studies. However,
in the situation in which patients will have access to the
treatments that are used in the study setting regardless of
whether the patient enrolls, prospective participants and
their referring physicians should be reassured: there is no
evidence that random treatment assignment leads to worse
clinical outcomes. Furthermore, patients who do participate
in such research can contribute to the important objective of
improving health and well-being for all patients.
Supporting Information
Protocol S1. Literature Search Keywords and Results
Found at DOI: 10.1371/journal.pmed.0030188.sd001 (67 KB DOC).
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Editors’ Summary
Background. When researchers test a new treatment, they give it to a
group of patients. If the test is to be fair and provide useful results, there
should also be a control group of patients who are studied in parallel.
The patients in the control group receive either a different treatment, a
pretend treatment (‘‘a placebo’’), or no treatment at all. But how do
researchers decide who should be in the treatment group and who
should be in the control group? This is an important question because
the test would not be fair if, for example, all the individuals in the
treatment group were elderly men and the controls were all young
women, or if everyone in the treatment group received their treatment
in a well-equipped specialist hospital and the controls received care in a
local general hospital. Statisticians would say that the results from such
studies were ‘‘confounded’’ by the differences between the two groups.
Instead, patients should be allocated to treatment or control groups at
random. Randomization also has the advantage that it can conceal from
the researchers, and from the patients, whether the treatment being
given is the new one or an old one or a placebo. This is important
because—again for example—researchers might hold strong beliefs
about the effectiveness of a new treatment and this bias in its favor
might lead them, perhaps only subconsciously, to allocate younger,
stronger patients to the treatment group. For these and other reasons,
randomized clinical trials (RCTs) are regarded as the ‘‘gold standard’’ in
assessing the effectiveness of treatments.
Why Was This Study Done? Doctors normally decide on the ‘‘best’’
treatment for an individual patient based on their knowledge and
experience. However, if a patient has agreed to be part of an RCT, then
their treatment will instead be chosen at random. Some people worry
that patients who participate in RCTs may, because their treatment is less
‘‘personalized,’’ have a lower chance of recovery from their illness than
similar patients who are not in trials. In contrast, other argue that,
particularly if the trial is part of an important research program, being in
an RCT is to the patient’s advantage. This study aimed to find out
whether either of these possibilities is true.
What Did the Researchers Do and Find? The researchers conducted a
thorough electronic search of medical journals in order to find published
RCTs for which information—both before and after treatment—had
been recorded not only about the patients who were enrolled in the
trials, but also about other patients whose condition made them eligible
to participate but who were not actually enrolled. The researchers also
decided in advance that they were only interested in such RCTs if the
non-enrolled patients had access to the same treatment or treatments
that were given to the trial participants. Only 25 RCTs were found that
met these requirements. There were nearly 18,000 patients in these
studies; overall 45% had received treatment after randomization and
55% had not been randomized. Most of the RCTs were for treatments for
cancer, problems of the heart and circulation, and obstetric and
gynecological issues. The ‘‘clinical outcomes’’ recorded in the trials
varied and included, for example, death/survival, recurrence of cancer,
and improvement of hearing. In 22 of these trials, there were no
statistically significant differences in clinical outcomes between patients
who received random assignment of treatment (i.e., the RCT participants)
and those who received individualized treatment assignment (eligible
non-participants). In one trial the randomized patients fared better, and
in the remaining two the nonrandomized patients had the better
outcomes.
What Do These Findings Mean? These findings suggest that
randomized treatment assignment as part of a clinical trial does not
harm research participants, nor does there appear to be an advantage to
being randomized in a trial.
Additional Information Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030188.
  The James Lind Library has been created to help patients and
researchers understand fair tests of treatments in health care by
illustrating how fair tests have developed over the centuries
  Wikipedia, a free Internet encyclopedia that anyone can edit, has pages
on RCTs
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